# Pizarra — PT-pseudo_2ef22b5dd08e (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_2ef22b5dd08e
Task: 1

Encounter: Urology - outpatient on 18 Feb 2025.
Referrer: Dr. C. Peters (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 66-year-old male
  - PSA: 9.3 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.296 ng/mL²
  - PSA velocity: 1.34 ng/mL/yr
  - Prior PSA: 6.2 ng/mL
  - Prostate volume: 31.46 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8335312 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 9.3 ng/mL. PI-RADS 4. PSAD 0.30. Prostate volume 31 mL. csPCa 0.83.

Vitals: weight 75 kg, height 184 cm, BMI 22.2, BP 136/76 mmHg, HR 71 bpm. Smoking: Ex-smoker (24 pack-yr, quit 2020).

Chief complaint: Clinical reassessment indicated due to a persistent upward PSA trajectory coupled with recent multiparametric magnetic resonance imaging results.

History: At 66 years of age, this semi-retired harbour pilot seeks review concerning his prostate-specific antigen trajectory, accompanied by a longstanding record of moderate lower urinary tract symptoms (IPSS 8/35). He shares an assisted-living residence with his spouse, who serves as his main point of contact. Physical activity remains a priority, featuring three weekly cycling sessions covering roughly 30 km each, balanced with an alcohol intake of 8 units weekly. His smoking history totals 24 pack-years, though he ceased tobacco use in 2020. Ocular limitations necessitate large-print documents. Recent medical engagements include a gastroenterology visit for standard colonoscopy screening, pulmonary function testing, and a baseline chest radiograph. A laparoscopic gallbladder removal occurred in 2015, entirely separate from his present urological evaluation. He maintains no active comorbidities, takes no prescribed medications, manages occasional seasonal allergies with non-prescription antihistamines, and carries no prior biopsy history. No unexplained weight reduction, skeletal discomfort, or blood in the urine has been reported. General health otherwise appears stable.

Physical examination: Per rectum: Normal DRE; digital assessment reveals a uniformly enlarged gland exhibiting consistent firmness without discrete irregularities or lateralised masses. Cardiovascular and respiratory auscultation demonstrate regular rhythms and clear field expansion. Abdominal percussion and palpation confirm a pliable, non-tender cavity lacking palpable hepatosplenomegaly or abnormal growths.

Patient info: harbour pilot (semi-retired); Married; Lives in assisted-living facility.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 8 units / week; exercise Cycling 3x/week, ~30 km; IPSS score: 8/35 (moderate LUTS).

Recent other appointments: Gastroenterology — surveillance colonoscopy; Radiology — chest X-ray (routine); Pulmonary function test — known COPD follow-up.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.93 +/- 0.04   (95% CI 0.86-1.00)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.04  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.37 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'firm': p +/- 1.96*dp does not cross the 0.5 threshold. Treat it as a strong prior that should only be overturned by explicit contradicting evidence. Measured accuracy in this tier on the labelled cohort: 1.0 over 28 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI show a PI-RADS 3 or higher lesion?
  - psa_trend (get_psa_trend) -> Is the PSA velocity or trend significant enough to warrant biopsy?
  - previous_notes (get_previous_notes) -> What was the prior management context and agreed-upon surveillance pathway?

This case hinges on the interpretation of the PI-RADS score, the PSA trajectory, and the prior management plan to determine the necessity of a biopsy.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered the structured panel, failing to weigh the clinical context of the rising PSA velocity (1.34 ng/mL/yr) against the PI-RADS 4 score and the high csPCa probability (0.8335). It did not account for the patient's history of moderate LUTS (IPSS 8/35) or his age (66), which might influence the risk tolerance for biopsy.

WHY THE SUGGESTION COULD BE WRONG
The prior suggests biopsy based on a high probability (0.93), but the guideline track record is based on a biopsy-naive cohort. The guideline criterion is PI-RADS $\ge 3$, which is met, but the prior does not account for the PSA velocity or the specific PSA density (0.296 ng/mL²), which are crucial modifiers in risk-adapted strategies. The high aleatoric uncertainty (H=0.37) suggests the model struggles with the data distribution, potentially over-weighting the PI-RADS score without sufficient context on the PSA trajectory.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report (get_mri_report) -> Must confirm the specific PI-RADS score and characterize the lesion morphology, as the guideline hinges on PI-RADS $\ge 3$.
psa_trend (get_psa_trend) -> Must quantify the significance of the PSA velocity (1.34 ng/mL/yr) relative to the guideline's implicit thresholds.
previous_notes (get_previous_notes) -> Must establish the prior management context to determine if the current situation warrants a repeat biopsy or a new approach.
laboratory panel (get_laboratory_results) -> Must confirm the PSA density (0.296 ng/mL²) and ensure no other relevant lab markers are present.
GUIDELINE ANCHOR
The guideline states to biopsy when the mpMRI shows a PI-RADS 3 or higher lesion, and this decision is constrained by PSA density thresholds and family history.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: PI-RADS 4 lesion in the left peripheral zone (base-to-mid), 14 mm. Prostate volume: 31.46 mL. PSA density: 0.296 ng/mL/mL. csPCa predicted probability 0.8335312.
get_psa_trend
PSA trend: [{"date": "Jul 2022", "val": 6.7}, {"date": "May 2023", "val": 4.0}, {"date": "Apr 2024", "val": 4.4}, {"date": "Feb 2025", "val": 9.3}]
get_previous_notes
Previous notes: {"date": "21 Oct 2024", "author": "Dr. C. Peters (GP)", "text": "21 Oct 2024 - General Practitioner: Clinical check-in focused on tracking prostate-specific antigen levels. The most recent measurement, obtained in April 2024, registered at 6.2 ng/mL, indicating a decline from earlier highs. Urinary symptoms remain absent beyond his established lower urinary tract complaints.", "date": "01 Mar 2023", "author": "Dr. C. Peters (GP)", "text": "01 Mar 2023 - General Practitioner: Office visit initiated to address rising prostate-specific antigen values. Laboratory data returned a level of 8.7 ng/mL. Digital rectal assessment yielded normal findings."}

NOT RETRIEVED
laboratory_results
Laboratory results were not retrieved because the moderator's agenda did not explicitly require them, and the retrieved documents did not raise a specific question requiring this panel (e.g., regarding free-PSA or renal function before an invasive procedure).

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 4 lesion in the left peripheral zone (base-to-mid), 14 mm.
- PSA trend: PSA velocity is high, with a jump from 4.4 ng/mL in Apr 2024 to 9.3 ng/mL in Feb 2025.

AGAINST sampling this patient now:
- Previous notes: Patient was on a surveillance pathway, and the last documented PSA was 6.2 ng/mL in Oct 2024, suggesting a recent decline before the current elevation.

WHERE THIS LEANS
The evidence strongly supports sampling due to the high-risk MRI finding (PI-RADS 4) and the significant, recent upward trajectory in the PSA level.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=yes, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence (PI-RADS 4 lesion and significant PSA velocity) strongly supports the decision to biopsy, aligning with the guideline criterion. However, the laboratory results were not retrieved, which remains a missing piece of context.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to biopsy is supported by convergence across all inputs. The guideline criterion mandates biopsy for a PI-RADS 4 lesion, which was retrieved from the MRI report. This was reinforced by the significant PSA velocity, showing a jump from 4.4 ng/mL to 9.3 ng/mL. The statistical prior also strongly suggested biopsy, and the retrieved evidence confirmed the high-risk imaging finding, leading to a clear consensus.

Variables that carried weight: age=important, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
